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Background: The primary objective of this study was to test whether oncolytic herpes simplex virus type 1 (HSV1)
could eradicate chemoresistant cancer stem cells (CSCs).
Methods: The fluorescent aldefluor reagent-based technique was used to identify and isolate ALDHbr cells as CSCs
from the 4T1 murine breast cancer cell line. The presence of ALDHbr 4T1 cells was also examined in 4T1 breast
cancer transplanted in immune-competent syngeneic mice.
Results: Compared with ALDHlo cells, ALDHbr cells had a markedly higher ability to form tumor spheres in vitro and
a higher tumorigenic potential in vivo. ALDHbr cells also exhibited increased doxorubicin resistance in vitro, which
correlated with a selective increase in the percentage of ALDHbr cells after doxorubicin treatment and an increased
expression of P-glycoprotein (P-gp), a known chemoresistance factor. In contrast, oncolytic HSV1 was able to kill
ALDHbr cells in vitro and even more markedly in vivo. Furthermore, in in vivo studies, systemic administration of
doxorubicin followed by intratumoral injection of oncolytic HSV1 resulted in much more significant suppression of
tumor growth with increased median survival period compared with each treatment given alone (p<0.05). Though
more CD8+ T lymphocytes were induced by oncolytic HSV1, no significant specific T cell response against CSCs was
detected in vivo.
Conclusions: These results suggested that the use of oncolytic HSV1 following doxorubicin treatment may help
eradicate residual chemoresistant CSCs in vivo.
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Breast cancer is the 3rd most commonly diagnosed type
of cancer and the leading cause of cancer death among
females aged 20 to 59 years old [1]. With the improve-
ment of early detection and/or comprehensive treat-
ment, the breast cancer death rate has been greatly
reduced. However, there are no effective therapeutic
treatments once cancer is recurrent or metastatic. Cancer
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reproduction in any medium, provided the orcancer progression, recurrence, metastasis and resistance
to a number of conventional therapies [2-7]. CSCs have
been identified in many tumor types and cell lines based
on the expression of unique cell surface markers such as
CD44, CD24 and CD133 or their ability to efflux lipo-
philic, fluorescent dyes such as Hoechst 33342 [8-11]. An-
other useful approach for the identification of CSCs is
based on a high level of aldehyde dehydrogenase
(ALDHbr) activity, which has been associated with che-
moresistance and poor prognosis in many types of cancer
[12-18]. The 4T1 mouse breast cancer cell line was chosen
for this study because its growth and metastatic spread in
mice closely mimic stage IV human breast cancer [19].
Several markers, including Sca-1 and ALDHbr, have beenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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this study, we used ALDHbr to identify and isolate CSCs
from 4T1 cells. Because most conventional treatment regi-
mens, including chemotherapy, target the non-CSC popu-
lation of the tumor and fail to eliminate CSCs [5,6],
discovering new ways to eliminate CSCs that are left be-
hind following chemotherapy is important. The use of
oncolytic viruses (OVs) is likely the treatment of choice
[22-24]. OVs are either naturally occurring or genetically
engineered viruses that selectively infect and lyse tumor
cells without deleterious effects on normal cells [25,26]. In
the OV family, the oncolytic herpes simplex virus type 1
(HSV1) is one of the most extensively studied, and it has
strong oncolytic activity and promising therapeutic effects
[27-29]. Given that the anticancer mechanism of viral
oncolysis differs from that of chemotherapeutic agents, we
reasoned that chemoresistant CSCs may be still treatable
to oncolytic HSV1 [30-34]. In this study, we compared the
role of oncolytic HSV1 and doxorubicin in the eradication
of CSCs in vitro and in vivo and then employed doxorubi-
cin to kill non-CSCs, followed by oncolytic HSV1 admin-
istration to eradicate residual chemoresistant CSCs
in vivo. CD8+ cytotoxic T lymphocytes (CTLs) have been
shown to play a critical role in immunity against cancer
and viruses [35-37]. We therefore further investigated
whether the immunological mechanism induced by our
oncolytic HSV1 mediated the eradication of CSCs.Methods
Cells and drugs
4T1, a mammary gland tumor cell line from Balb/c mice
with high metastatic potency, was purchased from
ATCC. 4T1 cells were maintained in DMEM/F12 sup-
plemented with 10% FCS and gentamycin at 37°C in a
humidified atmosphere of 5% CO2. The cells were sub-
cultured at a ratio 1:6–8 when they were close to 80%
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italics. The reverse-complement sequences present in ICP34.5USr and ICP34.5DSf fo3rd-6th passages in the log growth phase were used for
experiments.
Doxorubicin, a classic chemotherapy agent for human
breast cancers, was purchased from Shenzhen Main
Luck Pharmaceuticals Inc. and prepared at 1.5 mg/ml in
saline just prior to use.
Construction of recombinant oncolytic HSV1-GFP and
HSV1-hGM-CSF
Oncolytic HSV1-GFP and HSV1-hGM-CSF, constructed
in our laboratory, were attenuated oncolytic herpes sim-
plex type 1 viruses (17+, ECACC 0104151v). All virus
vectors were grown in BHK-21 [C13] (ATCC: CCL-10)
or Vero (ATCC: CCL-81) cells in DMEM/F12 containing
10% FCS. Viral DNA was purified using DNAzol (Bio-
Teke Corporation, China).
To construct HSV1-GFP and HSV1-hGM-CSF, the
genes encoding infection cell protein 34.5 (ICP34.5) and
ICP47 were removed, the expression cassette for human
granulocyte–macrophage colony-stimulating factor (hGM-
CSF) or green fluorescent protein (GFP) was inserted into
the sites for ICP34.5.
To delete ICP47, the up-stream (US) and down-stream
(DS) flanking regions (FLRs) were amplified from 17+
virus genome with primer pairs ICP47USf versus
ICP47USr and ICP47DSf versus ICP47DSr, respectively
(Table 1). Then the EcoRI/SpeI-digested US and HindIII/
SalI-digested DS FLRs were jointed together with the
complemented Linker 1/2 (Table 1) and subsequently
cloned into pBluescript (Stratagene) EcoRI and SalI sites
to create pdICP47, which was then sequencing verified.
The eGFP expression cassette under control CMV pro-
moter released from pcDNA3.1-eGFP (YRGENE, China)
by EcoRI/XhoI double digestion and treated with T4 DNA
polymerase was cloned into pdICP47 EcoRV site to gener-
ate pdICP47-eGFP.
Upon the removal of ICP47, 17+ strain viral DNA and
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tor (17-d47-GFP) expressing eGFP was purified with
four round plaque assays. At each round, 4–6 single pla-
ques were picked under fluorescent microscope. With
similar procedure, the 17-d47 vector (Figure 1) with the
eGFP expression cassette removed was constructed by
co-transfection of 17-d47-GFP viral DNA and pdICP47.
To delete ICP34.5, the US and DS FLRs were amplified
from 17+ strain genome with primer pairs ICP34.5USf
versus ICP34.5USr and ICP34.5DSf versus ICP34.5DSr,
respectively (Table 1). Then the ICP34.5 US and DS FLRs
were jointed together using an overlapping PCR with the
primer pair ICP34.5USf/ICP34.5DSr and subsequently
inserted into pSP72 (Promega) pre-digested with BamHI/
XhoI and treated with T4 DNA polymerase for blunt-end
cloning. The resulted plasmid was named as pdICP34.5
and sequencing verified. The hGM-CSF gene (Invivogen)
was used to replace eGFP of pcDNA3.1-eGFP giving
plasmid pcDNA3.1-hGM-CSF. The eGFP and hGM-CSF
expression cassettes from pcDNA3.1-eGFP and pcDNA3.1-
hGM-CSF were cloned into pdICP34.5 AfeI site to generate
pdICP34.5-eGFP and pdICP34.5-hGM-CSF, respectively.
The pdICP34.5-eGFP and pd.ICP34.5-hGM-CSF were used
to delete ICP34.5 from 17-d47 vector giving viruses
HSV1-GFP and HSV1-hGM-CSF (Figure 1).
Flow cytometry sorting of cells with ALDHbr activity
4T1 cells were harvested, and a single-cell suspension was
obtained for the aldefluor assay according to the manufac-
turer's instructions (Stem Cell Technologies). Briefly, 106
cells were resuspended in 1 ml of aldefluor assay buffer
containing activated aldefluor substrate. As a negative con-
trol for each sample, an aliquot of “aldefluor-exposed” cellsFigure 1 Schematic construction of oncolytic HSV1-GFP and HSV1-hG
17+ strain. First, the ICP47 gene was removed from the virus genome by p
pdICP34.5-eGFP was inserted into both sites for ICP34.5 genes to generate
was used to replace GFP expression cassettes in HSV1-GFP to create HSV1-was immediately quenched with a specific ALDH inhibi-
tor, diethylaminobenzaldehyde (DEAB). Following a 30-
minute incubation at 37°C, the cells were centrifuged, the
pellets were resuspended in 0.5 ml aldefluor assay buffer,
and the ALDHbr and ALDHlo subpopulations were sorted
using a FACSDiVa flow cytometer (Becton Dickinson).Mammosphere formation assay
4T1 or isolated cells were resuspended in DMEM/F12
serum free medium (SFM) supplemented with human
recombinant epidermal growth factor (EGF; 20 ng/ml)
and basic fibroblast growth factor (bFGF; 20 ng/ml) and
then seeded in ultra-low attachment 6-well plates
(Costar, Corning Incorporated) with 5 × 104 cells/well in
2 ml. Both EGF and bFGF were purchased from Sigma
Biochemicals. Fresh aliquots of EGF and bFGF were
added every other day. After 8 days of culture, mammo-
spheres were observed. Carboxymethyl cellulose (CMC)
was added at a final concentration of 0.8% to keep the
fluid flow slow, and the spheres were quantified using an
inverted phase contrast microscope (Olympus Co.).Tumorigenicity studies with isolated cells
The sorted ALDHbr and ALDHlo cells were resuspended,
serially diluted in DMEM/F12 SFM and inoculated sub-
cutaneously (s.c.) into the right flanks of 6-7-week-old
immune-competent female Balb/c mice (n=5-6) at vary-
ing numbers (5, 000, 1, 000 and 100) in a volume of 100
μl. The tumor-initiating capacity of the two populations
was monitored weekly and compared. Animals were
euthanized when tumors exceeded 1, 800 mm3 or the
60-day endpoint was reached.M-CSF. The two oncolytic HSV1 vectors were developed from
dICP47-eGFP and pdICP47. Then, the GFP expression cassette from
HSV1-GFP. The hGM-CSF expression cassette from pdICP34.5-hGM-CSF
hGM-CSF.
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Both ALDHbr and ALDHlo subpopulations isolated from
4T1 cells were washed with phosphate-buffered saline
(PBS). The cells were collected by centrifugation, and the
pellet was suspended in RIPA lysis buffer (Biomiga, Inc.)
containing a cocktail of proteinase inhibitors i.e., leupeptin,
aprotinin and pepstatin (the first two agents were pur-
chased from Roche, and pepstatin was purchased from
Amresco). The cells were lysed on ice for 15 minutes. The
lysates were centrifuged at 12, 000 rpm for 10 minutes at
4°C, and the protein in the supernatant was collected. The
protein concentration was quantified using the bicinchoni-
nic acid (BCA) assay kit (Applygen Technologies, Inc.) to
ensure that equal amounts of protein from both subpopu-
lations were loaded in the gel. The remaining supernatants
were boiled in sample buffer containing sodium dodecyl
sulfate (SDS) and β-mercaptoethanol and then used for
western blot analysis.
Western blot analysis was performed as previously
described with slight modifications [38]. Briefly, the
proteins were separated using a 7% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).
Following electrophoresis, the samples were transferred
onto a polyvinylidene difluoride (PVDF) membrane.
After the transfer, non-specific binding sites were blocked
at room temperature for 1 hour with 5% non-fat dry
milk in PBS with gentle agitation. The membranes were
incubated overnight at 4°C with the following primary
antibodies: monoclonal mouse anti-P-gp (JSB-1, Abcam)
(1:200 dilution in 3% non-fat dry milk) and anti-β-actin
(1:1, 000 dilution, Zhongshan goldenbridge biotechnology
Co., Ltd.), which was used for normalization. The mem-
brane was washed with PBS (3 × 10 minutes) and then
incubated with a horseradish peroxidase-conjugated goat
anti-mouse IgG (1:5, 000 dilution, Zhongshan golden-
bridge biotechnology Co., Ltd.) for 1 hour at room
temperature with gentle agitation followed by rinsing as
before. The protein bands were visualized using an
enhanced chemiluminescence (ECL) detection system
(Applygen Technologies Inc.), according to the manufac-
turer’s instructions, followed by exposure to X-ray film.
In vitro cytotoxicity of oncolytic HSV1
For 4T1 monolayers, the day before infection, 2 × 105
4T1 cells were seeded into 6-well plates. After a 24-hour
incubation, the cells of one well were trypsinized and
counted to facilitate the calculation of the MOIs for in-
fection. The media in the other wells were replaced with
1 ml fresh DMEM/F12 SFM containing viruses at differ-
ent MOIs. One control well was added only DMEM/F12
SFM. After a 1-hour incubation, 1 ml of DMEM/F12 full
growth medium (FGM) was added to each well. The
CPE was observed at different times after infection using
an inverted phase contrast microscope.For the mammospheres, after 7 days of culture, 4T1
mammospheres of one well were collected and digested
with AccutaseW solution (Sigma), and the cells were
counted to calculate the MOIs for virus infection. The
mammospheres of the other wells were infected with
HSV1-GFP at an MOI of 1, and a well with the addition
of vehicle was used as a control. HSV1-GFP was directly
added without changing the medium. The GFP expres-
sion was observed at different time points.
For ALDHbr and ALDHlo cells, the cells were resus-
pended in DMEM/F12 FGM and seeded into dishes (33
mm in diameter) at a density of 5 × 104 cells/ml in
2 ml/dish. The media was then replaced with 1 ml of
fresh DMEM/F12 SFM containing HSV1-GFP at differ-
ent MOIs when most cells were adherent. One control
dish contained DMEM/F12 SFM only. After a 1-hour in-
cubation, the medium was changed with 2 ml of fresh
DMEM/F12 FGM, which contained just 3% FCS to keep
the cells alive but to slow cell differentiation. After incu-
bation for another 10 hours, GFP expression was exam-
ined, and images were obtained using an inverted
fluorescence microscope.Establishment of a subcutaneous cancer model and
tumor therapy protocols
5–6 weeks old immune-competent female Balb/c mice
were obtained from the Institute of Zoology, Chinese
Academy of Sciences. All protocols for the animal
experiments were approved by the Animal Care and Use
Committee of the Cancer Institute and Hospital, Chinese
Academy of Medical Sciences. All mice were housed and
handled according to the institutionally recommended
guidelines. A total of 5 × 104 4T1 cells were s.c. injected
into the right flank of mice. After 4–5 days, when
tumors appeared, the mice were distributed by tumor
size into the following treatment groups (n=12-13 per
group): (a) doxorubicin followed by HSV1, (b) doxorubi-
cin alone, (c) HSV1 alone and (d) control. Chemother-
apy with 8 mg/kg doxorubicin was i.v. administered
twice at days 0 and 3. Oncolytic HSV1-hGM-CSF treat-
ment at a dose of 1 × 107 plaque forming units (PFU)
per mouse was subsequently given by direct intratu-
moral injection on days 5, 7, 9, 11 and 13. We treated
the control mice with the solvent for doxorubicin and
oncolytic HSV1 (NS and DMEM/F12 SFM, respectively).
The primary tumor size and body weight were routinely
measured every 4 days following treatment. The tumor
volume was calculated using the following formula:
tumor volume (mm3) = [L × W2] / 2, where L equals
length and W equals width in mm.
After the third treatment with oncolytic HSV1-hGM-
CSF (on day 11), the primary tumors were surgically
removed from each group (n=4-5) and used for the
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were used for the survival analysis (n=5-7).
Flow cytometry analysis of 4T1 cells with ALDHbr activity
4T1 cells at a density of 1 × 105 cells/ml were seeded
in T-75 cm2 cell culture flasks at 15 ml/flask. On the sec-
ond day, the medium was changed with fresh DMEM/
F12 FGM, and the cells were cultured for an additional
24 hours in the presence or absence of doxorubicin (1.0
μg/ml) or HSV1-hGM-CSF (MOI=0.3). The controls
were incubated with vehicle only. Then the cells were
harvested, and a single-cell suspension was obtained for
the aldefluor assay as described above.
Primary tumor tissue comprising 4T1 cells was isolated,
minced into tiny fragments and digested with collagenase
IV (1 mg/ml) and DNase I (300 U/ml) (all obtained from
Sigma) for approximately 1.5 hours at 37°C in 5% CO2
with intermittent pipetting. The single cells obtained by
filtering through a 200-mesh screen were lysed with
Ammonium Chloride Solution (Stem Cell Technologies)
to exclude red blood cells. After the aldefluor assay was
performed, the cells were stained with APC anti-mouse
CD45 (BioLegend) and its isotype antibody at 4°C for 30
minutes to exclude leukocytes. The ALDHbr cells were
then analyzed by flow cytometry as described above.
Characterization of CD8+ T lymphocytes in splenocytes by
flow cytometry analysis
After the second treatment with oncolytic HSV1 (on day
8), the spleens (n=3-4) were surgically removed and used
for CD8+ T lymphocyte measurement, and their cytotox-
icity to 4T1 ALDHbr cells was measured by flow cytome-
try. The single cell suspension was prepared through a
400-gauge mesh. Lymphocytes from the spleens were
isolated by centrifugation in gradient lymphocyte isola-
tion solution for mice (Tianjin Hao Yang Biological
Manufacture Co., Ltd., China) at room temperature and
washed twice with PBS. The cell suspensions in PBS
were then stained at 4°C for 30 minutes using the fol-
lowing antibodies: FITC anti-mouse CD3, PE anti-
mouse CD8b and their corresponding isotype control
antibodies (all monoclonal antibodies were obtained
from Biolegend). After washing with PBS, the cells were
fixed with 10% formaldehyde and the CD8+ T lympho-
cyte frequency was determined by flow cytometry.
CTL cytotoxicity assay by flow cytometry
In vitro CTL detection was performed as previously
described with some modification [39]. ALDHbr cells
were sorted from 4T1 cells on the day of the assay. To
label target cells, the isolated cells were resuspended in
PBS containing 5-(and −6) -carboxyfluorescein diacetate
succinimidyl ester (CFSE, Sigma) at a final concentration
of 10 μmol/l and incubated at 37°C/5% CO2 for 10minutes. After incubation, the reaction was stopped by
adding a large volume of DMEM/F12 FGM, and the la-
beled target cells were then washed in DMEM/F12 FGM
to sequester any free CFSE. After resuspension in
DMEM/F12 FGM, the cell number and viability were
assessed using trypan blue exclusion, and the cell con-
centration was adjusted to 2 × 104 viable cells/100 μl
with DMEM/F12 FGM. Effector cells (lymphocytes)
were obtained from euthanized tumor-bearing mice
from the different treatment groups as described above.
Isolated lymphocytes were washed and resuspended in
DMEM/F12 FGM, the cell number and viability were
assessed as described above, and the cell concentration
was adjusted to 2 × 106 viable cells/100 μl. Effector and
target cells were mixed at an E:T ratio of 100:1 (2 × 106
for effector cells and 2 × 104 for target cells, respect-
ively) in a total volume of 200 μl per test. After incuba-
tion for 3.5 hours at 37°C/5% CO2, DMEM/F12 FGM
was added to a final volume of 0.5 ml and stained with
propidium iodide (PI, Sigma) at a final concentration of
2 μg/ml. Finally, cytotoxicity against the target cells was
assessed by flow cytometry. The determination of cyto-
toxicity was based on enumeration of dead target cells
(CFSE+PI+). To determine specific lysis, the survival of
allogeneic splenocytes in tumor-free naive mice was used
as a baseline. All of the assays were performed in
triplicate.Statistical analysis
All statistical tests were performed using GraphPad
Prism 5 software. The Student's unpaired t-test was per-
formed on the following experimental data: the frequency
of ALDHbr cells and CD8+ T lymphocytes and tumor vol-
ume. The results are presented as the mean ± SEM
(standard error of the mean). The Kaplan–Meier method
and the log-rank test were used to compare survival,
which was defined as the time from tumor inoculation
until the endpoint. All statistical tests were two-sided, and
statistical significance was defined as a p < 0.05.Results
The scheme for construction of the two recombinant
oncolytic viruses, HSV1-GFP and HSV1-hGM-CSF, is
shown in Figure 1. They are attenuated by the deletion
of both copies of the ICP34.5, which is neurovirulence
gene, and of ICP 47 gene. Deletion of gene encoding
ICP34.5 provides tumor selectivity. ICP47 functions to
block antigen processing in HSV1 infected cells, and
therefore deletion of it is aiming to improve anti-tumor
immunity [40]. Deletion of ICP47 also results in the
US11 gene being under the control of the ICP47 imme-
diate early promoter that results in enhanced virus repli-
cation. Insertion of GFP gene or hGM-CSF is to serve as
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stimulating potency, respectively.
4T1 ALDHbr cells have CSC characteristics
In some tumor cells, including 4T1 cells, the ability to
form spherical aggregates (“spheres”) in non-adherent
culture conditions has been shown to be a characteristic
of CSCs [41-43]. In this study, CSCs were identified and
isolated from 4T1 cells using the aldefluor assay. To de-
termine whether these sorted 4T1 cells with high
ALDH1 enzymatic activity, termed “ALDHbr” cells, are
bona fide CSCs, two aspects were examined: the
mammosphere-forming ability in vitro and tumorigen-
icity in vivo. ALDHbr and ALDHlo 4T1 subpopulations
were isolated by flow cytometry (Figure 2A). As shown
in Figures 2B and C, ALDHbr cells gave rise to approxi-
mately 3-fold more tumorspheres than the ALDHlo cells
when the mammospheres were larger than 25 μm in
size. In addition, mammospheres larger than 50 μm were
only produced by ALDHbr cells.
The tumorigenic ability in vivo is the gold standard for
identifying CSCs, and it has been studied in many
tumors [44,45]. To investigate the possible difference in
tumor formation potential between the ALDHbr and
ALDHlo subpopulations, serial dilutions of both subpo-
pulations were s.c. injected into Balb/c mice (as
described above). Both subpopulations were able to form
tumors when 5, 000 or more cells were implanted
(Table 2). However, when 1, 000 or fewer cells were
implanted, the frequency of tumor formation was higher
for ALDHbr than for ALDHlo cells. At the 1, 000-cell di-
lution, the ALDHbr cells formed tumors in 5/5 mice,
whereas the ALDHlo cells formed tumors in 2/5 mice.
Remarkably, as few as 100 ALDHbr cells were able to
form tumors in 4/6 mice, whereas the same number of
ALDHlo cells failed to generate tumors in any mice (0/6)
over 2 months.
Collectively, the 4T1 ALDHbr cells had increased
mammosphere-forming capacity and tumor-initiating po-
tency compared with ALDHlo cells; thus, they possessed
CSC properties.
4T1 ALDHbr cells are resistant to chemotherapy
CSCs are responsible for resistance to conventional
chemotherapy. P-gp is considered to play an important
role in the development of chemoresistance in breast
cancer [46]. Western blot analysis was performed to de-
termine the expression of P-gp in the sorted ALDHbr
and ALDHlo subpopulations of 4T1 cells. The expression
of P-gp was significantly elevated in ALDHbr cells when
compared with the corresponding ALDHlo cells in which
P-gp expression was not detectable, whereas there was
no significant change in the expression of β-actin in
both subpopulations (Figure 3). The different expressionlevels of P-gp might well explain why 4T1 ALDHbr cells
were chemoresistant.Both 4T1 monolayers and mammospheres are infectable
to HSV1 in vitro
To investigate the infection of 4T1 mammospheres by
oncolytic HSV1, HSV1-GFP was used to easily observe
infected mammospheres with green fluorescence. First,
the cell-killing ability of HSV1-GFP against 4T1 tumor
cell monolayers was investigated in vitro. By 24 hours
after infection, the infected monolayer cells displayed a
marked CPE (nearly 85% at an MOI of 0.5, 95% at an
MOI of 1) compared with control mock-infected cells
(Figure 4A). Typical CPE cells can be characterized by
rounded and contracted shapes, detachment from one
another, or even detachment from the tissue culture
plate.
Mammosphere cultures from the 4T1 cell line were
established and infected by oncolytic HSV1-GFP. Strong
green fluorescence due to constitutive GFP expression
was detected in many cells of the spheres compared with
the mock-infected control (Figure 4B). At an MOI of 1
for 24 hours, HSV1-GFP could infect a few cells of
mammospheres, while at a later time of infection (48
hours), it had spread into more cells of the mammo-
spheres. Collectively, these data indicate that both 4T1
monolayers and mammospheres can be infected by
oncolytic HSV1-GFP.ALDHbr and ALDHlo cells can be uniformly infected by
HSV1-GFP
4T1 cells stained with aldefluor substrate demonstrated
bright green fluorescence, which could not be distin-
guished from the GFP expression in cells infected with
HSV1-GFP. However, the green fluorescence quickly dis-
appeared from post-sorted ALDHbr cells because they
were no longer in the aldefluor buffer, which blocked
ABC transporters and retained the fluorescent substrate
in the cells, but were instead in sheath fluid and medium
when plated in dishes. Therefore, the isolated ALDHbr
cells were fluorescent-free and HSV1 drived GFP expres-
sion could be used to evaluate the HSV1 infectivity to
ALDHbr cells. Sorted ALDHbr and ALDHlo cells were
infected with HSV1-GFP at different MOIs for different
times. As shown in Figure 4C, after 10 hours, GFP ex-
pression had appeared in both subpopulations infected
with HSV1-GFP at MOIs of 0.3 and 1. After infection
for 34 hours, when cell proliferation and differentiation
had occurred, GFP expression was more apparent in
both subpopulations. Moreover, the HSV1-GFP infection
efficiency in both ALDHbr and ALDHlo cells was similar
(38.8% for ALDHbr cells versus 29.4% for ALDHlo cells,
respectively, p=0.0664, n=4-6).
Figure 2 (See legend on next page.)
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(See figure on previous page.)
Figure 2 4T1 ALDHbr cells have high mammosphere-forming ability. (A) Representative flow cytometry plots demonstrating the sorting of
4T1 cells with high (ALDHbr, P2, 3~5% of P1 gate) and low ALDH activity (ALDHlo, P3, 3~5% of P1 gate). The first gate (P1) chooses the cells with
good status from the total cells and excludes cell debris according to their FSC & SSC values. The cells were incubated with an aldefluor substrate
(BAAA), and the specific inhibitor of ALDH, DEAB, was first used to establish the baseline fluorescence level of ALDH activity (top). Staining of 4T1
cells with aldefluor substrate but without DEAB inhibitor produced a shift in BAAA fluorescence that defined the ALDHbr population (bottom).
(B) ALDHbr (left) and ALDHlo (right) cells were plated for mammosphere formation (5 × 104 cells/well) for 8 days. Mammospheres were observed
using an Olympus inverted phase contrast microscope (40 × objective magnifications). (C) The data shown are the average number of spheres
counted in different sizes from a representative experiment performed in duplicate wells.
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treatable to HSV1 in vitro and in vivo
To further examine the effect of oncolytic HSV1 on 4T1
ALDHbr cells, 4T1 cells were treated with doxorubicin (1.0
μg/ml) or HSV1-hGM-CSF (MOI=0.3) for 24 hours (when
a similar CPE, approximately 30%, appeared in both trea-
ted cells, data not shown) and subsequently investigated
for changes in the proportion of ALDHbr cells by flow
cytometry. Because of the overlapping fluorescence be-
tween the activated aldefluor substrate (Figure 5A) and
GFP expression by flow cytometry, oncolytic HSV1-hGM-
CSF was used instead. There was a 3.5-fold increase in the
proportion of ALDHbr cells after treatment with doxorubi-
cin (up to 46.42%) versus the corresponding control
(13.17%) (n=3, p<0.0001, Figures 5B and C). However, the
presence of HSV1-hGM-CSF in the medium did not sig-
nificantly alter the percentage of ALDHbr cells in the 4T1
cells (11.22%) compared with the control (n=3, p=0.47).
The results demonstrated that 4T1 ALDHbr cells, which
could be significantly enriched by doxorubicin in vitro,
could be uniformly killed by oncolytic HSV1.
To determine whether these ALDHbr tumor cells also
exhibited resistance to doxorubicin chemotherapy or
sensitivity to HSV1-hGM-CSF in vivo, the ALDHbr
tumor cell frequency was examined in vivo after differ-
ent treatments. Inconsistent with the in vitro data, there
was no further increase in the ALDHbr tumor cell fre-
quency in vivo after the chemotherapy-alone treatment,
which was similar to, or even slightly less than, those of
the tumors treated with vehicle (29.56% for doxorubicin
versus 32.10% for vehicle, n=3, p>0.05) (Figures 6A and
B). In contrast, oncolytic HSV1-hGM-CSF single-agent
therapy resulted in a significant decrease in the ALDHbr
tumor cell content (18.71%, n=3, p<0.05 for HSV1 versus
control), and the frequency of the ALDHbr tumor cellsTable 2 Tumor-initiating capacity of freshly sorted
ALDHbr versus ALDHlo subpopulations in vivo
Subpopulation ALDHbr ALDHlo
Cell numbers 5, 000 1, 000 100 5, 000 1, 000 100
Tumor incidence 5/5 5/5 4/6 5/5 2/5 0/6
Serial dilutions of ALDHbr versus ALDHlo cells were s.c. injected into female
Balb/c mice, and tumor growth was observed weekly and compared. The
tumor formation frequency between both subpopulations was plotted against
the number of cells injected (i.e., 5, 000, 1, 000 and 100 cells).was also dramatically reduced in tumors treated with
doxorubicin followed by HSV1-hGM-CSF (21.49%) versus
vehicle or doxorubicin alone (n=3, p<0.05).
ALDHbr subpopulation increased with the development of
a primary tumor in vivo
We speculated that the reason the percentage of ALDHbr
4T1 cells in the control group was unexpectedly high
(32.10%, Figure 6B) may be because of their larger tumor
volume. Therefore, 4T1 tumor-bearing mice with different
primary tumor volumes (1 week and 2 weeks after the
tumor occurred) were selected, and the change in the per-
centage of ALDHbr 4T1 cells in the primary tumors was
analyzed. As expected, the frequency of ALDHbr tumor
cells grew with the development of primary tumors
(Figure 6C). The mean primary tumor volume was 73.0
mm3 at 1 week and 360.5 mm3 at 2 weeks after the tumor
appeared (n=3, p=0.0437), and the frequency of ALDHbr
tumor cells was 10.02% and 17.11%, respectively (n=3,
p<0.0001). Therefore, the percentage of ALDHbr 4T1 cells
increased with the growth of primary tumors.
CD8+ T lymphocytes induced by HSV1 does not appear to
be responsible for ALDHbr tumor cell eradication
To explore whether the eradication of ALDHbr tumor
cells was mediated by CD8+ T lymphocytes generated inFigure 3 Western blot analysis demonstrated increased P-gp
expression in 4T1 ALDHbr cells. The western blot analysis was
performed as described in the Methods section. P-gp (141 kDa)
expression was significantly increased in 4T1 ALDHbr cells compared
with ALDHlo cells. β-actin served as the loading control. The
experiment was performed in duplicate with similar findings
obtained in each experiment. A representative blot is shown.
Figure 4 HSV1-GFP was highly oncolytic to 4T1 monolayers, mammospheres and isolated ALDHbr and ALDHlo cells. (A) 4T1 cells were
infected with HSV1-GFP at different MOIs (0, 0.01, 0.1, 0.5 and 1) for 24 hours. The images were visualized using a phase-contrast microscope (top)
and a fluorescence microscope for GFP expression (bottom). (B) After a 7 day culture, 4T1 mammospheres were infected with HSV1-GFP at an
MOI of 1. At 24 (middle) and 48 (lower) hours after infection, the spheres exhibited a GFP signal compared with the mock-infected control
(upper). The images were visualized using phase-contrast (left) and fluorescence microscopy (right). (C) Sorted ALDHbr and ALDHlo cells were
infected by HSV1-GFP at different MOIs (0, 0.1, 0.3 and 1). The cell morphology and GFP expression were visualized using an inverted
fluorescence microscope, and overlapping images were taken at 10 (left panels) and 33 hours (right panels) after infection (100 × objective
magnifications).
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Figure 5 The effect of different in vitro treatments on 4T1 ALDHbr cells was assessed using flow cytometry. (A) 4T1 cells stained with the
aldefluor substrate were imaged using phase-contrast (left) and fluorescence microscopy (right) (100 × objective magnifications). (B) An aldefluor
assay of ALDHbr in 4T1 cells treated with either doxorubicin (1.0 μg/ml, middle), HSV1-hGM-CSF (MOI=0.3, right), or media alone (Mock) (left).
The upper images in each column are the DEAB-treated negative control, and the lower pictures are the corresponding experimental sample.
(C) The ALDHbr cell frequency in the presence of doxorubicin or HSV1-hGM-CSF was compared with the control. The data represent the
mean ± SEM of three independent experiments. ***, p<0.001 for a significant difference between the doxorubicin-treated group and the other
two groups. Abbreviations: DOX, doxorubicin; OV, HSV1-hGM-CSF.
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Figure 6 The influence of doxorubicin and/or HSV1-hGM-CSF on ALDHbr tumor cells in vivo. (A) An aldefluor assay of ALDHbr in
in vivo-treated primary tumors as described in the Methods section. Representative images of flow cytometry from the four groups are depicted.
The upper panels are the gates to exclude APC anti-mouse CD45+ leukocytes. The percent of CD45- cells was as followed: 33.45% for DOX+OV,
58.89% for DOX, 56.54% for OV and 61.69% for Control. (B) The mean frequency of ALDHbr tumor cells in the four groups are as follows (n=4-5).
The experiment was performed twice with similar findings. (C) The influence of the primary tumor volume on 4T1 ALDHbr cells in vivo. The mean
tumor volume (left), and the mean percentage of ALDHbr tumor cells (right, n=3-5) both increased with time. The data represent the mean ±
SEM in triplicate. *, p < 0.05; ***, p < 0.001. Abbreviations: DOX, doxorubicin; OV, HSV1-hGM-CSF.
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CD8+ T lymphocyte percentage and activity after differ-
ent treatments.
Flow cytometric analysis of the frequency of CD8+ T
lymphocytes in spleens from mice with different treat-
ments and their results were followed. As shown in
Figure 7A, treatment with either doxorubicin or onco-
lytic HSV1 had a marked effect on the CD8+ T
lymphocyte frequency in the spleens (23.63% and21.40%, respectively) compared with the control group
(17.53%) (n=3, p<0.05). The CD8+ T lymphocyte fre-
quency in spleens treated with doxorubicin demon-
strated a slight elevation compared with that of the
oncolytic HSV1 group, but no significant difference
existed (n=3, p>0.05). The proportion of CD8+ T lym-
phocytes demonstrated a greater increase in mice trea-
ted with doxorubicin followed by oncolytic HSV1
(28.37%; n=3; p<0.05).
Figure 7 Cytotoxic activity to 4T1 ALDHbr of CD8+ T
lymphocytes from mice following different therapies. (A) The
proportion of CD8+ T lymphocytes in spleens after treatments.
(B) CD8+ T lymphocyte cytotoxicity to 4T1 ALDHbr by CFSE/PI flow
cytometry. Negative control splenocytes were taken from tumor-free
naive mice. Statistical analysis was performed using the unpaired
Student’s t test: *, p < 0.05; **, p < 0.01; ns, not significant.
Abbreviations: DOX, doxorubicin; OV, oncolytic HSV1-hGM-CSF;
TLs, T lymphocytes; NC, negative control.
Figure 8 Anticancer effect of doxorubicin and/or HSV1-hGM-
CSF against 4T1 breast tumors. The mice bearing 4T1 tumors
were treated with doxorubicin and/or HSV1-hGM-CSF as described
in the Methods section. (A) The tumor volume of mice among the
different groups was measured every 4 days following treatments.
The data represent the mean ± SEM (n=6). Arrows indicate the type
of treatments: thick arrows for doxorubicin chemotherapy and thin
arrows for oncolytic HSV1-hGM-CSF treatment. (B) The median
survival times for the 4 groups are illustrated in Kaplan–Meier
survival curves (n=5-7). ***, p < 0.001. The experiment was
performed twice with similar findings. Abbreviations: DOX,
doxorubicin; OV, HSV1-hGM-CSF.
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strated significant cytotoxic activity to 4T1 ALDHbr cells
with an E/T ratio of 100:1 (24.17%) (n=3, p<0.05), while
lymphocytes from mice treated with oncolytic HSV1 did
not seem to demonstrate significant CTL activity against
the same target cells at the same E/T ratio (12.27%),
which was even less than that of the control group
(20.13%) (n=3, p<0.05) (Figure 7B). Moreover, cytotoxic
activity induced by doxorubicin plus oncolytic HSV1
treatment increased slightly compared with the nonspe-
cific cytotoxicity (14.67% versus 9.80%, respectively; n=3;
p>0.05), which was also lower than that of the control
group (n=3, p>0.05).
Doxorubicin followed by HSV1 demonstrated the greatest
therapeutic effect in vivo
The above observations provided a rationale for further
evaluating the treatment modalities with respect to theiroverall anticancer effects in vivo. 4T1 breast tumors
treated with either doxorubicin or oncolytic HSV1-
hGM-CSF experienced a significant reduction in tumor
volume compared with the vehicle-treated control group
(n=6, p<0.001). Moreover, the combined treatment
resulted in a more significant reduction in tumor vol-
ume compared with the other two treatment groups
(n=6, p≤0.0001) (Figure 8A). No statistical significance
was observed between the doxorubicin-alone and HSV1-
hGM-CSF-alone treatment groups.
None of the animal tumors completely regressed, and
all animals died due to excessive tumor growth. Mice
treated with doxorubicin or HSV1-hGM-CSF alone
demonstrated a prolonged median survival time com-
pared with mock-treated mice (35 days for the control
group, 39.5 days for the doxorubicin-alone group and 40
days for the HSV1-alone group; n=5-7; p<0.05, log-rank
test) (Figure 8B). The median survival time between
mice that received either treatment alone was not sig-
nificantly different. For the combination group, the me-
dian survival time was significantly longer (47 days)
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versus doxorubicin-alone, p>0.05 versus HSV1-alone,
log-rank test). The results above demonstrated that
treatment with either doxorubicin or HSV1 exhibited
significant anticancer effects, and the combination treat-
ment group demonstrated the greatest anticancer effi-
cacy in vivo.
Discussion
CSC chemoresistance has become the main obstacle in
successful anticancer treatment and is largely respon-
sible for human breast cancer mortality [47-49]. Cells
with high ALDH1 activity have been shown to possess
CSC characteristics in many tumor types [13-18]. In our
study, ALDHbr cells isolated from 4T1 cells were shown
to have CSC properties, including their mammosphere-
forming ability in vitro and tumorigenicity in vivo. In
addition, CSCs typically overexpress cell membrane
ATP-binding cassette (ABC) drug transporters such as
P-gp, which mediate the efflux of a large number of
cytotoxic compounds, including doxorubicin. Our study
indicated that P-gp expression was only detected in 4T1
ALDHbr cells.
Among the therapeutic agents used for human breast
cancer, doxorubicin, an anthracycline drug, remains a
first-line choice [50,51]. Despite its excellent anticancer
activity in the clinic, doxorubicin treatment is con-
fronted with toxicities, including severe myelosuppres-
sion and dose-cumulative cardio-toxicity [52-54]. Most
importantly, similar to many other chemotherapeutic
drugs, the treatment of breast cancer with doxorubicin
was unable to eradicate CSCs but instead led to an en-
richment of CSCs [55,56]. HSV1 is a potent oncolytic
virus that has been evaluated in many types of tumors in
mice and humans [27-29,57]. We compared the effects
of oncolytic HSV1 and doxorubicin on the ALDHbr
population in vitro and in vivo. Our in vitro results, in
agreement with previous reports [55,56,58], indicated
that doxorubicin can enrich the CSCs of 4T1 cells,
which were still treatable by oncolytic HSV1. Phenotypic
analysis revealed an obvious decrease in the frequency of
ALDHbr tumor cells in mice treated with oncolytic
HSV1. It has been reported that oncolytic HSV can in-
duce a robust anti-tumor immune responses against 4T1
mammary tumors in vivo [27,59,60] and CTLs mediated
cytotoxicity to cancer cells [35]. In our study, though the
CD8+ T lymphocyte frequency in spleens treated with
oncolytic HSV1 demonstrated a significant elevation
compared with the control group, no significant specific
CTL response appeared to participate in ALDHbr cell
elimination. This may be due to the following reasons:
(1) The CD8+ T lymphocytes induced by oncolytic
HSV1 may be mainly specific to the virus itself (a strong
immunogen compared with 4T1 cells) and this wassupported by marked splenomegaly observed after onco-
lytic virus alone treatment (data not shown), and (2) the
hGM-CSF carried by oncolytic HSV1 was ineffective in
mice due to species differences [61]. Unexpectedly, there
was no increase in the percentage of ALDHbr cells in
tumors treated with doxorubicin alone compared with
those treated with vehicle. This unexpected result may
be due to the following factors: (1) The time between
the last chemotherapy and aldefluor assay was too long
(8 days) to exam the enrichment of CSCs from doxo-
rubicin, (2) Doxorubicin by itself can enhance the antic-
ancer immune response [62,63] and may also enhance
the anti-CSC activity (Figure 7B), which may explain
why ALDHbr subpopulation in the doxorubicin-treated
group was not greater than that of the control group,
and (3) The larger primary tumor volume in vehicle-
treated control mice may influence the percentage of
ALDHbr tumor cells due to tumor necrosis or hypoxia
[64]. In our study, it was demonstrated for the first time
that the frequency of ALDHbr tumor cells increased with
the development of primary tumors in 4T1 tumor-
bearing mice.
Although our oncolytic HSV1 can reduce the primary
4T1 tumor volume effectively, which is consistent with
the previous reports [27,59,60,65,66], and decrease the
frequency of ALDHbr cells compared with chemother-
apy, it also has its own limitations, including physical
barriers such as the extracellular matrix, which restrict
the initial distribution and subsequent spread of viruses
in the tumor mass when the oncolytic virus is directly
injected into the tumor, and anti-HSV1 immunity, which
can limit virus replication when locally or systematically
given repeatedly [67,68]. These limitations may be over-
come by combination of viral and chemotherapies.
Ideally, the combined therapies could lead to synergistic
effects in the following considerations: (1) The majority
of the non-CSCs were first eradicated by chemotherapy
and then the residual CSCs were killed by oncolytic
HSV1. (2) Oncolytic viral replication and subsequent
spread in the tumor mass may be enhanced by chemo-
therapy leading to antiviral immune response inhibition,
the destruction of physical barriers, alteration in the
tumor cell physiology and induced activation of DNA re-
pair pathways [34,69,70]. (3) Oncolytic viruses circum-
vent typical chemoresistance mechanisms, they may be
effective for chemoresistant CSCs [22,71]. (4) Chemo-
therapy and oncolytic HSV1 with different mechanisms
of action could synergistically act to kill cancer cells and
thus may achieve much more efficient antitumor activity
[70,72]. In our in vivo study, treatment with doxorubicin
chemotherapy followed by oncolytic HSV1 achieved
more significant benefits than either single agent alone.
(5) Oncolytic HSV1 had slight and different toxicities
compared with chemotherapy [73]. The combination of
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[70,74]. In our experiment, the administration of oncoly-
tic HSV1-hGM-CSF alone was well tolerated, and admin-
istering HSV1-hGM-CSF followed by doxorubicin did
not enhance the toxicity of the latter (Additional file 1:
Figure S1). The strategy of targeting CSCs with oncolytic
HSV1-hGM-CSF in combination with standard chemo-
therapy that kills non-CSCs may be applied to the treat-
ment of human breast cancer in the clinic.
Conclusion
In conclusion, this study suggested that 4T1 ALDHbr
cells possess CSC characteristics. These ALDHbr cells
were doxorubicin-resistant but still treatable to oncolytic
HSV1. The treatment of 4T1 breast tumors with oncoly-
tic HSV1 followed by doxorubicin chemotherapy gener-
ated a potent anticancer effect in vivo.
Additional file
Additional file 1: Figure S1. Toxicity comparison of four different
treatment groups in vivo.
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